10-Q: Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Clinical Program Update

Spruce Biosciences reports a net loss of $20.8 million for the first half of 2024, while advancing its clinical programs for tildacerfont.

Summary

• Spruce Biosciences is a late-stage biopharmaceutical company focused on developing therapies for endocrine and neurological disorders.
• The company's lead product candidate is tildacerfont, an oral antagonist of the CRF 1 receptor.
• For the six months ended June 30, 2024, Spruce Biosciences reported a net loss of $20.8 million and used $26.1 million in operating activities.
• As of June 30, 2024, the company had cash and cash equivalents of $69.7 million.
• The company believes its current cash will fund operations for at least 12 months following the issuance date of the financial statements.
• Spruce Biosciences is conducting clinical trials for tildacerfont in classic congenital adrenal hyperplasia (CAH), polycystic ovary syndrome (PCOS), and major depressive disorder (MDD).
• The CAHmelia-203 trial did not meet its primary endpoint and was terminated, while CAHmelia-204 and CAHptain-205 trials are ongoing with topline results expected in the fourth quarter of 2024.
• A Phase 2 trial in PCOS showed a significant reduction in DHEAS and an increase in SHBG versus placebo.
• A Phase 2 proof-of-concept study of tildacerfont in MDD is being funded and conducted by HMNC Holding GmbH.
• The company has a license agreement with Kaken Pharmaceutical Co. Ltd. for the development and commercialization of tildacerfont for CAH in Japan, which included an upfront payment of $15 million in April 2023.
• Spruce Biosciences anticipates needing to raise substantial additional financing in the future to fund its operations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are some positive developments in clinical trials and collaborations, the company's financial losses and the termination of a key trial raise concerns. The need for future capital raises also adds uncertainty.

Positives

• The company believes its current cash will fund operations for at least 12 months following the issuance date of the financial statements.
• A Phase 2 trial in PCOS showed a significant reduction in DHEAS and an increase in SHBG versus placebo.
• HMNC Holding GmbH is funding and conducting a Phase 2 proof-of-concept study of tildacerfont in MDD patients.
• The company received a $15 million upfront payment from Kaken Pharmaceutical Co. Ltd. in April 2023.

Negatives

• Spruce Biosciences reported a net loss of $20.8 million for the six months ended June 30, 2024.
• The CAHmelia-203 trial was terminated after not meeting its primary efficacy endpoint.
• The company anticipates needing to raise substantial additional financing in the future to fund its operations.

Risks

• The company has a limited operating history and has incurred significant net losses since its inception.
• The company is dependent on the success of tildacerfont, its only product candidate.
• Clinical trials may fail to demonstrate the safety and efficacy of tildacerfont.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• Delays in clinical trials could increase costs and limit the ability to generate revenue.
• The company may not be successful in expanding its pipeline or identifying additional indications for tildacerfont.
• The market opportunities for tildacerfont may be smaller than anticipated.
• The company currently has no marketing and sales organization.
• The company is highly dependent on key personnel.
• The company relies on third parties to conduct clinical trials and manufacture its product.
• The company may not be able to obtain and maintain sufficient intellectual property protection.
• Unfavorable economic conditions could adversely affect the company's business.

Future Outlook

The company believes its current cash will fund operations for at least 12 months following the issuance date of the financial statements. Topline results from the CAHmelia-204 and CAHptain-205 trials are expected in the fourth quarter of 2024. The company anticipates needing to raise substantial additional financing in the future to fund its operations.

Management Comments

• The company believes its current cash will fund operations for at least 12 months following the issuance date of the financial statements.

Industry Context

The biopharmaceutical industry is characterized by intense competition and rapid innovation. Spruce Biosciences is competing with other companies developing treatments for endocrine and neurological disorders, including those targeting classic CAH. The company is also seeking strategic collaborations to benefit from the resources of biopharmaceutical companies specialized in either relevant disease areas or geographies in markets outside the United States.

Comparison to Industry Standards

• Neurocrine Biosciences, Inc. is developing a CRF 1 receptor antagonist and filed NDAs in adult and pediatric classic CAH with target action dates in December 2024.
• Crinetics Pharmaceuticals, Inc. initiated a Phase 2 clinical trial in 2023 to evaluate the safety and efficacy of an oral ACTH antagonist in adults with CAH and reported positive interim data.
• BridgeBio Pharma, Inc. is evaluating an AAV5 gene therapy product candidate to treat classic CAH in a Phase 1/2 proof-of-concept clinical trial.
• Spruce Biosciences is also investigating tildacerfont for the treatment of classic CAH in children, with topline results from additional dose ranging cohorts expected in the fourth quarter of 2024.

Stakeholder Impact

• Shareholders may experience dilution due to potential future capital raises.
• Employees may be affected by potential changes in the company's operations and financial condition.
• Patients may benefit from the development of new therapies for endocrine and neurological disorders.
• Creditors may be impacted by the company's financial performance and ability to repay debt.

Next Steps

• The company plans to meet with the FDA and comparable foreign regulatory authorities to outline the design of a registrational clinical program in adult and pediatric classic CAH, assuming positive results from CAHmelia-204 and CAHptain-205.
• Topline results from the CAHmelia-204 and CAHptain-205 trials are anticipated in the fourth quarter of 2024.
• The company is evaluating strategic collaboration opportunities for the development and commercialization of tildacerfont for the treatment of PCOS.

Key Dates

Keywords

tildacerfont, congenital adrenal hyperplasia, CAH, polycystic ovary syndrome, PCOS, major depressive disorder, MDD, clinical trials, biopharmaceutical, CRF 1 receptor antagonist, endocrine disorders, neurological disorders